Candidate Clinical Correlate of Prognostic Outcome for TB Study

Recruiting now

Conditions studied: Tuberculosis

In brief

As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.

Key facts

Study ID

NCT07018076

Run by

University of California, San Francisco

People needed

750

Starts

2025-11-25

Expected to finish

2027-05-31

Last updated by the study team

2026-07-20

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• . individuals age ≥ 12 years;
• . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).

You may not qualify if…

• completed treatment for drug-susceptible tuberculosis >14 days prior to screening/enrollment;
• routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days;
• unwilling to provide informed consent or return for study follow-up visits.

Where it is running

• Kisenyi Health Center — Kampala, Uganda (enrolling)
• Mulago Outpatient Department — Kampala, Uganda (enrolling)
• Hanoi Lung Hospital, Outpatient departments — Hanoi, Vietnam

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.